Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank100
3Y CAGR+35.4%
5Y CAGR+19.6%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+35.4%/yr
vs +8.2%/yr prior
5Y CAGR
+19.6%/yr
Recent acceleration
Acceleration
+27.2pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
3 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1.99 | +33.0% |
| 2024 | 1.50 | +48.6% |
| 2023 | 1.01 | +25.5% |
| 2022 | 0.80 | -33.6% |
| 2021 | 1.21 | +48.9% |
| 2020 | 0.81 | -0.9% |
| 2019 | 0.82 | +39.9% |
| 2018 | 0.59 | -41.5% |
| 2017 | 1.00 | -5.2% |
| 2016 | 1.06 | - |